COMPANY

Glucotrack

Profile checked Oct 10, 2026

Keywords: Diabetes Mellitus Sensor Lead

Raises and deals from press releases

Raise Undisclosed round · $11.5M · announced Sep 11, 2026 Company release ↗
Source quote
- Sep 11, 2026 · Company release ↗
  “(NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5 million, including approximately $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over”
Raise Undisclosed round · about $5.5M · announced Aug 5, 2026 Company release ↗
Source quote
- Aug 5, 2026 · Company release ↗
  “(NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced definitive agreements for approximately $5.5 million in financing from participating institutional investors”

Raises announced in these releases: $11.5M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Sep 24, 2026 Raise Follow-on offering: $3.1M (total, as published), announced Sep 24, 2026. Source: SEC filing. source ↗
Sep 11, 2026 Raise Undisclosed round · $11.5M source ↗
Aug 5, 2026 Raise Undisclosed round · about $5.5M source ↗
Apr 3, 2025 Partnership Partnership / licensing announced Apr 3, 2025. Source: company's own press page. source ↗
Feb 4, 2025 Raise Follow-on offering: $3M (total, as published), announced Feb 4, 2025. Source: company's own press page. source ↗
Dec 13, 2024 Trial start Not phased (device or behavioral study): Feasibility Study to Evaluate an Intravascular Blood Continuous Glucose Sensor source ↗
Nov 14, 2024 Raise Follow-on offering: $10M (total, as published), announced Nov 14, 2024. Source: SEC filing. source ↗

Raised: $16.1M. Last 2 years.

Sep 24, 2026 Follow-on offering: $3.1M (total, as published), announced Sep 24, 2026. Source: SEC filing. source ↗
Feb 4, 2025 Follow-on offering: $3M (total, as published), announced Feb 4, 2025. Source: company's own press page. source ↗
Nov 14, 2024 Follow-on offering: $10M (total, as published), announced Nov 14, 2024. Source: SEC filing. source ↗
Apr 3, 2025 Partnership / licensing announced Apr 3, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06764069	Feasibility Study to Evaluate an Intravascular Blood Continuous Glucose Sensor	Not phased (device or behavioral study)	Recruiting	Dec 13, 2024	Feb 4, 2025 (estimated)